On Controlled Release Society (CRS) 2023 annual meeting, Triastek’s co-founder and CSO, Professor Xiaoling Li gave a poster presentation on “Solubility and Bioavailability Enhancement of Poorly Soluble Drugs Using Melt Extrusion Deposition (MED^®) 3D Printing Technology”

Triastek established 3D Microstructure for Solubility Enhancement (3DμS^TM-SE) technology platform. By using MED process, specifically by 3D drug microstructure design and other techniques, amorphous solid dispersion (ASD) can be produced, compartment or grid tablet design can be developed, which can effectively prolong the supersaturation time of poorly soluble APIs, and further enhance the in-vivo bioavailablility.